Dive Brief: Atlas Venture, a prolific creator of biotech startups, has raised $450 million to form and invest in new drug companies, announcing Thursday the …
Dive Brief: Roche is expanding clinical testing of its experimental Alzheimer’s disease drug gantenerumab, announcing Thursday the start of a late-stage trial in people with …
Dive Brief: Karyopharm Therapeutics will have to perform a new clinical trial to widen the use of its cancer drug selinexor after U.S. regulators said …
Dive Brief: AstraZeneca and Daiichi Sankyo’s antibody drug Enhertu could become standard treatment for a large group of breast cancer patients following Phase 3 study …
Dive Brief: Adagio Therapeutics CEO Tillman Gerngross has agreed “in principle” to resign as head of the COVID-19 drug developer amid confusion over whether its …
Dive Brief: An experimental, fast-acting depression drug from Sage Therapeutics and partner Biogen met its main goals in a closely watched Phase 3 study that …
Dive Brief: Al Sandrock, a former top Biogen executive who led development of the company’s Alzheimer’s drug Aduhelm, is joining the board of directors at …
At a quick glance, the Food and Drug Administration’s decision to ask its advisers for help in vetting yet another cancer immunotherapy may seem odd. …
Gilead lost several billion dollars in market value Wednesday after unnerving investors with updates about a key clinical trial of its most closely watched breast …
Gilead lost several billion dollars in market value Wednesday after unnerving investors with updates about a key clinical trial of its most closely watched breast …
Biogen recorded $1 million in revenue from its new treatment for Alzheimer’s disease in the last quarter of 2021, offering the latest evidence that the …
Dive Brief: Eli Lilly is pushing back the timing for when it expects to finish submitting an application for U.S. approval of its experimental drug …
Dive Brief: The Food and Drug Administration on Tuesday granted approval to the first drug for a rare cancer of the eye that has spread …
Dive Brief: Incyte is pulling its application for an experimental lymphoma medicine after determining that the Food and Drug Administration’s requirements for confirmatory studies would …
Dive Brief: The Food and Drug Administration has ordered California biotech Cortexyme to stop testing of an experimental Alzheimer’s disease drug, notifying the drugmaker in …
Dive Brief: EQRx, which aims to bring new medicines to market at “radically lower” prices, said the experimental lung cancer drug it co-owns with Chinese …
Biotechnology stocks ended the first day of the J.P. Morgan Healthcare Conference in the green, but only barely. By Monday afternoon, a closely followed index of …
The company’s shares plummeted by more than 40% in early Thursday trading after taking a hit earlier in the week when the FDA released the …
Faced with the failure of a key clinical trial, a California-based biotech is pressing ahead with plans to test its experimental Alzheimer’s drug in another …
Novartis’ testing of canakinumab, which works by curbing inflammatory signaling in cells, for the seemingly unrelated use in lung cancer stems from an intriguing 2011 …
